Buradasınız

Anasayfa » Content

Tip 2 Diyabette İnsülin Tedavisinin Etkinliğini Belirleyen Faktörler

PREDICTIVE FACTORS FOR SUCCESSFUL INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Objective: Predictive factors for successful insulin therapy in type 2 diabetic patıents with poor glycemic control despite using maximum dose of oral antidiabetic therapy were investigated. Method: One hundred forty five patients (age 57.00+11.05 yrs, body mass index (BMI) 28.8+5.4 kg/m2, diabetes durati¬on 11.6+7.8 yrs) with type 2 diabetes according to WHO cri¬teria using insulin therapy for at least 6 months because of poor glycemic control with maximum dose of oral antidiabetic drugs for a minimum of 6 months were included in the study. Fasting blood sugar, basal c-peptide level, HbA1c, blo¬od presure, BMI, and serum lipids were evaluated before and after insulin therapy. Results: Fasting blood sugar and HbA1c levels decreased significantly after insulin treatment (p<0.001, for both). The ove¬rall increase in body weight was about 4.3 kg (p<0.001). When we evaluated the patients at the end of the second ye¬ar of insulin treatment, there were a strong correlation betwe¬en the age of onset of diabetes, insulin treatment beginning age, diabetes duration, and insulin requirement (r = 0.19, p<0.01, r = -0.24, p<0.05, r = -0.21, p<0.01). We also found significant correlation between diabetes duration, insulin tre¬atment beginning age (r = 0.90, p<0.01), and c-peptide levels (r = -0.37, p<0.01). Patients were divided into two groups ac¬cording to the age of onset of diabetes (group 1 t 40 yrs, gro¬up 2 >40 yrs). In the first group, HbA1c level and insulin requ¬irement were found to be high, although c-peptide levels we¬re low. Insulin treatment beginning age was found to be low compared to the second group. Patients with diabetes durati¬on longer than 10 years had poor metabolic control (HbA1c % 8.12+0.95, p<0.05) and low c-peptide levels (2.92+1.41 ng/ml, p<0.05). Conclusion: At the end of the second year of the insulin tre¬atment in type 2 diabetics, patients had weight gain about 4.3 kg despite good metabolic control values. Earlier age of onset of diabetes (especially t 40 yrs), longer diabetes durati¬on and high BMI were the independent predictors of the suc¬cessful insulin treatment.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Maksimal dozda oral antidiyabetik ilaç tedavisine rağmen istenilen kan şekeri regülasyonu sağlanamayan tip 2 diyabetli hastalarda, insülin tedavisinin etkinliğini belirleyen faktörlerin irdelenmesi. Gereç ve Yöntem: Çalışmaya WHO kriterlerine göre tip 2 diabetes mellitus tanısı konmuş, 6 aydan uzun süredir maksimal dozda oral antidiyabetik almasına rağmen istenilen düzeyde kan şekeri regülasyonu sağlanamadığı için insülin tedavisine geçilen ve en az 6 aydır insülin tedavisi alan 145 hasta (yaş 57.00+11.05 yıl, vücut kitle indeksi (VKİ) 28.8±5.4 kg/m2, diyabet süresi 11.6+7.8 yıl) dahil edilmiştir. Açlık kan şekeri, bazal c-peptid düzeyi, HbA1c, kan basıncı, vücut ağırlığı ile serum lipidleri insülin tedavisine başlamadan önce ve takip periyo-dundaki son vizitte değerlendirilmiştir. Bulgular: Açlık kan şekeri (AKfi) ve HbA1c düzeyleri tedavi sonrasında anlamlı olarak azalmıştır (p<0.001, her ikisi için). Vücut ağırlığındaki ortalama artış 4.3 kg'dır (p<0.001). İnsülin tedavisinin ikinci yılı sonunda hastalar değerlendirildiğinde, di¬yabetin başlangıç yaşıyla insüline başlama zamanı, diyabet sü¬resi ve insülin ihtiyacı arasında belirgin korelasyon mevcuttu (r = 0.19, p<0.01, r = -0.24, p<0.05, r = -0.21, p<0.01). Diyabet süresi ile insüline başlama zamanı (r = 0.90, p<0.01) ve c-peptid düzeyleri arasında da belirgin korelasyon vardı (r = -0.37, p<0.01). Hastalar diyabet başlangıç yaşına göre 2 gruba ayrıldığında (grup 1140 yaş, grup 2>40 yaş), grup 1'de HbA1c düzeyleri ve insülin ihtiyacı yüksek, c-peptid düzeyi düşük bulun¬du. 10 yıldan daha uzun süredir diyabeti olan hastalarda me-tabolik kontrolün daha kötü olduğu (HbA1c % 8.12+0.95, p<0.05) ve c-peptid düzeyinin düşük olduğu görüldü (2.92+1.41 ng/ml, p<0.05). Yorum: Tip 2 diyabetlilerde insülin tedavisinin ikinci yılı değer¬lendirildiğinde metabolik kontrol iyi olmasına rağmen hastala¬rın kilo aldıkları (4.3 kg) tespit edildi. Diyabetin erken yaşta başlaması (özellikle t 40 yaş), daha uzun süredir diyabetik olmak ve yüksek VKİ değeri insülin tedavisine başlama zamanın¬da ve tedaviye cevapta bağımsız belirleyicilerdir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_6_pp_57-61.pdf
  • 2
57-61
  • Turkish

REFERENCES

References: 

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
2. Taylor SI, Accili D, Imor Y. Insulin resistance and or insulin deficiency which is the primary cause of NIDDM. Diabetes 1994; 43: 735 -39.
3. Unger RH, Grundy S. Hyperglycemia as an indicator as well as a consequence of impaired islet function and insulin resistance implications for the management of diabetes. Diabetologia 1985; 28: 119-21.
4. Robertson RP, Olsan CK, Zhang HJ. Differantiating glucose toxicity from glucose desensitization, a new message from the insulin gene. Di¬abetes 1994; 94: 1085-89.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-86.
6. Prando R, Odetti P, Melga P, Gusti R, Ciuchi E, Cheli V. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Diabetes & Metabolism 1996; 22: 185-91.
7. Groop LC, Pelkores R ve ark. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care
1986; 9: 201-5.
8. Sheen AJ, Castillo MJ, Lefebvre PJ. Assesment of residual insulin sec¬retion in diabetic patients using the intravenous glucagon stimulatory test: Methodological aspects and clinical applications. Diabetes & Metabolism
1996; 22: 397-406.
9. Clauson P, Linnarsson R, Gottsater A, Sundkvist G, Grill V. Relati¬onships between diabetes duration, metabolic control and b-cell function in a representative population of type 2 diabetic patients in Sweden. Di¬abetic Medicine 1994; 11: 734-801.
10. UK Prospective Diabetes Study (UKPDS 33). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treat¬ment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352 : 837-53.
11. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 1999; 22: 527-31.
12. Rosilio M, Cotton JB, Wieliczko MC ve ark. Factors associated with glycemic control. Diabetes Care 1998; 21: 1146-53.
13. Kovacs M, Koss RE, Schnell TM ve ark. Family functioning and me¬tabolic control of school-aged children with IDDM. Diabetes Care 1989;
12: 409-14.
14. Evans A, Krentz AJ. Benefits and risk of transfer from oral agents to insulin in type 2 diabetes mellitus. Drug Sof 1999; 21 (7): 7-22.
56 |
Selimoğlu ZÖ ve ark. | Tip 2 Diyabette İnsülin Tedavisinin Etkinliğini Belirleyen Faktörler
15. Pedock I, Tottersall RB. The difficult choice of treatment for poorly control¬led maturity onset diabetes: tablets or insulin. Br Med J 1984; 288: 1956-59.
16. Groop C, Widen E, Fransill-Kollunki A ve ark. Different effects of insu¬lin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1989; 32: 599-605.
17. Makimattilo S, Nikkula K, Yki-Jarvinen H. Causes of weight gain du¬ring insulin therapy with and without metformin in patients with type II
diabetes mellitus. Diabetologia 1999; 42: 406-12.
18. Yki-Jarvinen H, Kappila M, Kujanyuu E ve ark. Comparison of insu¬lin regimens in patients with non-insulin-dependent diabetes mellitus. N
Eng J Med 1992; 327: 1426-33.
19. Torbjörn L, Vaaler S. Optimal glycemic control in type 2 diabetic patients. Does including insulin treatment mean a better outcome?. Diabetes
Care 2000; 23 suppl 2: 30-4.
20. Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ ve ark. Prognostic fac¬tors for successful insulin therapy in subjects with type 2 diabetes. Meth J Med 1999; 54 (2): 63-9.
21. Nichols GA, Hillier TA, Javor K ve ark. Predictors of glycemic control in insulin-using adults with type 2 diabetes. Diabetes Care 1994; 7: 701-7.
22. Peng YS, Juang JH. Effects of insulin therapy on non-insulin-dependent diabetics with secondary oral hypoglicemic agent failure. Changgeng Yi Xue Zo Zhi 1998; 21(3): 271-6.

Thank you for copying data from http://www.arastirmax.com